BCL3ANT

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

BCL3ANT is an experimental anticancer drug which acts as an inhibitor of BCL3-mediated expression of cyclin D1, which is important for the proliferation and metastasis of certain types of cancer such as lymphoma and melanoma. BCL3ANT is of relatively low potency and is unlikely to be developed as a medicine in its own right, however as the first drug developed which inhibits BCL3-mediated cyclin D1 expression it is of academic interest in this area and is likely to lead to the development of more potent drugs acting through this pathway, which may be useful as anticancer medications.

BCL3ANT is an experimental anticancer drug which acts as an inhibitor of BCL3-mediated expression of cyclin D1, which is important for the proliferation and metastasis of certain types of cancer such as lymphoma and melanoma. BCL3ANT is of relatively low potency and is unlikely to be developed as a medicine in its own right, however as the first drug developed which inhibits BCL3-mediated cyclin D1 expression it is of academic interest in this area and is likely to lead to the development of more potent drugs acting through this pathway, which may be useful as anticancer medications.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370375558 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.